αVβ3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer
Abstract
alpha(v)beta(3) integrin-overexpression in tumor associated vasculature is a marker of poor prognosis in breast cancer. A positive correlation between alpha(v)beta(3) integrin and overexpression of Heregulin (HRG), a growth factor associated with breast cancer aggressiveness was recently demonstrated. Here, we addressed the role of alpha(v)beta(3) in the proliferation and survival of HRG-overexpressing breast cancer models. Expression of the RGD-binding integrins alpha(v)beta(3), alpha(v)beta(5) and alpha(v)beta(6) was assessed in the HRG-overexpressing breast cancer cells MDA-MB-231, Hs578T (231/WT and Hs578T/WT, respectively) and derived cells transfected with the antisense orientation of the HRG-beta2 full-length cDNA (231/ASPOOL, 231/AS31 and Hs578T/AS15). Interestingly, only alpha(v)beta(3) expression was noticeably decreased by blockade of HRG expression in the 231/ASPOOL, 231/AS31 and Hs578T/AS15 cells. Small RGD-based peptidomimetic alpha(v)beta(3) antagonists significantly decreased cell viability and anchorage-dependent cell growth of HRG-overexpressing cells, while the low-HRG-expressing 231/AS31 cells did not show a significant response. Mechanistically, functional blockade of alpha(v)beta(3) impaired HRG-promoted hyperactivation of ERK1/ERK2 MAPK without altering the activation of AKT. Flow cytometric analysis of the cell cycle demonstrated that alpha(v)beta(3) antagonists significantly decreased S- and G2/M-phase subpopulations of 231/WT and control 231/VEC cells. Comparable, this effect was linked to an increase in the levels and nuclear translocation of the CDKs inhibitor p27(Kip1). Besides downregulating alpha(v)beta(3) and its driven signaling, HRG blockade led to decreased levels of CYR61 in 231/ASPOOL and 231/AS31 cells. Considering that CYR61 is sufficient to upregulate the expression of alpha(v)beta(3), we then assessed alpha(v)beta(3) levels in MDA-MB-231 cell derivatives expressing the antisense orientation of the CYR61 cDNA (231/CYR61AS-5 and 231/CYR61AS-8). Remarkably, downregulation of CYR61 drastically decreased the levels of alpha(v)beta(3) in the 231/CYR61-5 and 231/CYR61-8 cells, providing further evidence of a key role for CYR61 in HRG-dependent alpha(v)beta(3) overexpression. Moreover, blockade of CYR61 expression impaired the HRG-induced hyperactivation of ERK1/ERK2 MAPK without altering the activation status of AKT in MDA-MB-231 cells, thus resembling the effects exerted by the downregulation of HRG expression as well as by functional blockade of alpha(v)beta(3). These results indicate that HRG is regulating alpha(v)beta(3) levels as well as alpha(v)beta(3)-triggered signaling through its downstream effector, CYR61, in highly invasive breast cancer cells. Altogether, the data presented here provide evidence of a CYR61-regulatory role on alpha(v)beta(3) integrin expression in the modulation of uncontrolled growth of HRG-overexpressing breast carcinomas. This work supports additional studies concerning the use of integrin antagonists as dual therapeutic agents in breast cancer, targeting both, endothelial and tumor cells.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CCN1 induces expression of integrin αvβ3.
“The anti-apoptotic functions of CCN1 in breast cancer cells are mediated through its receptor integrin αvβ3 [81,153], whose expression is also induced by CCN1 [154].”
From CCN1/CYR61: the very model of a modern matricellular protein (2011) · cites this paper as [154]
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,857 · see citing works
Role of integrins in cell invasion and migration
Hood, J. D., & Cheresh, D. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc727 · Cited by 1,781 · see citing works
Networks and crosstalk: integrin signalling spreads
Schwartz, M. A., & Ginsberg, M. H. (2002) · Nature Cell Biology · doi:10.1038/ncb0402-e65 · Cited by 797 · see citing works
Get a ligand, get a life: integrins, signaling and cell survival
Stupack, D. G., & Cheresh, D. A. (2002) · Journal of Cell Science · doi:10.1242/jcs.00071 · Cited by 580 · see citing works
Integrin activation controls metastasis in human breast cancer
Felding‐Habermann, B., O’Toole, T. E., Smith, J. W., Fransvea, E., Ruggeri, Z. M., Ginsberg, M. H., Hughes, P. E., Pampori, N. A., Shattil, S. J., Saven, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1853 · Cited by 578 · see citing works
Integrins: roles in cancer development and as treatment targets
Jin, H., & Varner, J. A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601576 · Cited by 574 · see citing works
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., & Cheresh, D. A. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200106070 · Cited by 554 · see citing works
Rolli, M., Fransvea, E., Pilch, J., Saven, A., & Felding‐Habermann, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633689100 · Cited by 333 · see citing works
Leu, S.-J., Lam, S. C.-T., & Lau, L. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209288200 · Cited by 247 · see citing works
Integrin Connections Map: To Infinity and Beyond
Martin, K. H., Slack, J. K., Boerner, S. A., Martin, C. C., & Parsons, J. T. (2002) · Science · doi:10.1126/science.296.5573.1652 · Cited by 235 · see citing works
Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone
Pécheur, I., Peyruchaud, O., Serre, C., Guglielmi, J., Voland, C., Bourre, F., Margue, C., Cohen-Solal, M. E., Buffet, A., Kieffer, N., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0911fje · Cited by 223 · see citing works
Lin, M.-T., Chang, C.-C., Chen, S.-T., Chang, H.-L., Su, J.-L., Chau, Y.-P., & Kuo, M.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402305200 · Cited by 194 · see citing works
Cyr61 promotes breast tumorigenesis and cancer progression
Tsai, M.-S., Bogart, D. F., Castañeda, J. M., Li, P., & Lupu, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205682 · Cited by 189 · see citing works
Self-citationStructure and function of RGD peptides involved in bone biology
Schaffner, P., & Dard, M. M. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s000180300008 · Cited by 179 · see citing works
Cruet-Hennequart, S., Maubant, S., Luis, J., Gauduchon, P., Staedel, C., & Dedhar, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206347 · Cited by 137 · see citing works
Buerkle, M. A., Pahernik, S. A., Sutter, A., Jonczyk, A., Messmer, K., & Dellian, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600141 · Cited by 125 · see citing works
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer
Tsai, M.-S., Shamon-Taylor, L. A., Mehmi, I., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206130 · Cited by 119 · see citing works
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis
Rüegg, C., Dormond, O., & Mariotti, A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.09.003 · Cited by 114 · see citing works
A small molecule antagonist of the α v β3 integrin suppresses MDA-MB-435 skeletal metastasis
Harms, J. F., Welch, D. R., Samant, R. S., Shevde, L. A., Miele, M. E., Babu, G. R., Goldberg, S. F., Gilman, V. R., Sosnowski, D. M., Campo, D. A., et al. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000024763.69809.64 · Cited by 109 · see citing works
Apoptotic cues from the extracellular matrix: regulators of angiogenesis
Stupack, D. G., & Cheresh, D. A. (2003) · Oncogene · doi:10.1038/sj.onc.1207110 · Cited by 106 · see citing works
Pereira, J. J., Meyer, T., Docherty, S. E., Reid, H. H., Marshall, J. F., Thompson, E. W., Rossjohn, J., & Price, J. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3056 · Cited by 96 · see citing works
Concept and progress in the development of RGD‐containing peptide pharmaceuticals
Craig, W. S., Cheng, S., Mullen, D. G., Blevitt, J., & Pierschbacher, M. D. (1995) · Biopolymers · doi:10.1002/bip.360370209 · Cited by 86 · see citing works
Targeted Mutagenesis of the Angiogenic Protein CCN1 (CYR61)
Leu, S.-J., Chen, N., Chen, C.-C., Todorović, V., Bai, T., Juric, V., Liu, Y., Yan, G., Lam, S. C.-T., & Lau, L. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407850200 · Cited by 72 · see citing works
Levkau, B., Kenagy, R. D., Karsan, A., Weitkamp, B., Clowes, A. W., Ross, R., & Raines, E. W. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401106 · Cited by 69 · see citing works
Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247
Shannon, K. E., Keene, J. L., Settle, S. L., et al. (2004) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000024764.93092.5f · Cited by 68 · see citing works
ERK1 Associates with αvβ3 Integrin and Regulates Cell Spreading on Vitronectin
Roberts, M. S., Woods, A. J., Shaw, P. E., & Norman, J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208607200 · Cited by 53 · see citing works
Ligand-dependent Activation of Integrin αvβ3
Butler, B., Williams, M. P., & Blystone, S. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206997200 · Cited by 38 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
CCN1/CYR61: the very model of a modern matricellular protein
Lau, L. F. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0778-3 · Cited by 338 · see citing works
Lee, H.-Y., Chung, J.-W., Youn, S.-W., Kim, J.-Y., Park, K.-W., Koo, B.-K., Oh, B.-H., Park, Y.-B., Chaqour, B., Walsh, K., et al. (2007) · Circulation Research · doi:10.1161/01.res.0000257945.97958.77 · Cited by 107 · see citing works
Zhao, N., Yang, Z., Li, B., Meng, J., Shi, Z., Li, P., & Fu, S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s104034 · Cited by 51 · see citing works
Sigala, F., Georgopoulos, S., Papalambros, E., Chasiotis, D., Vourliotakis, G., Niforou, A., Kotsinas, A., Kavantzas, N., Patsouris, E., Gorgoulis, V. G., et al. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.01.026 · Cited by 30 · see citing works
BAUERSCHMITZ, G., HÜCHEL, S., GALLWAS, J., & GRÜNDKER, C. (2023) · Cancer Genomics - Proteomics · doi:10.21873/cgp.20403 · Cited by 11 · see citing works
- Authors
- Vellon, L., Menendez, J. A., & Lupu, R.
- Affiliations
- Northwestern University (US)
- ORCID
- Lupu, Ruth
- Venue
- Oncogene
- Published
- 2005-03-14
- Volume
- 24
- Issue
- 23
- Pages
- 3759-3773
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1601996378
- Cited by
- 98
- References
- 27
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 9 · 2020: 4 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Northwestern University
- U.S. Public Health Service (R01-0490490)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Keywords
- integrin αvβ3, neuregulin-1, breast cancer, cell proliferation, cell survival, Akt signaling, p27, cell cycle arrest, CYR61, tumor vasculature, MDA-MB-231 cells
- MeSH terms
- Breast Neoplasms, Cell Survival, Female, Humans, Proto-Oncogene Proteins, Signal Transduction, Protein Serine-Threonine Kinases, Immediate-Early Proteins, Cell Cycle Proteins, Neuregulin-1, Tumor Suppressor Proteins, Intercellular Signaling Peptides and Proteins, Integrin alphaVbeta3, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Proto-Oncogene Proteins c-akt, Cysteine-Rich Protein 61
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
